Announced on December 1, 2025, for the three months ended September 30, 2025 (Q3 2025).
Reported net loss of $1,781,757 CAD.
R&D expenses: $1,102,371 CAD; G&A expenses:
$539,174 CAD.
Cash and cash equivalents as of September 30, 2025:
$822,293 CAD.
Key highlights include CNS-penetrant ATR inhibitor data presented at AACR-NCI-EORTC on October 27, 2025, and DTC eligibility on July 15, 2025.
Executive Chairman Jeffrey Bacha highlighted scientific milestones and momentum into 2026.